title: The potential of exosomes in immunotherapy of cancer.
abstract: Dendritic-cell-derived exosomes (DEX) secreted after dendritic cell loading with tumor peptides were found to mediate tumor rejection in mice. This observation prompted us to demonstrate that MHC class I/peptide complexes harbored onto exosomal membranes were capable of priming cytotoxic T cells and to mediate rejection of tumors expressing the relevant antigens. Moreover, DEX also promote NK cell activation in immunocompetent mice and NK cell-dependent antitumor effects. The first Phase I trial using DEX to immunize melanoma patients revealed the feasibility of DEX production in stage IV melanoma, their safety in long-term follow up and their bioactivity in vivo.
authors: ERIT-M 02-08 INSERM, Unité d'Immunologie, Département de Biologie Clinique, (+12), Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805 Villejuif, France.
authors: Nathalie
authors: N
authors: Chaput
authors: Julien
authors: J
authors: Taïeb
authors: Noël
authors: N
authors: Schartz
authors: Caroline
authors: C
authors: Flament
authors: Sophie
authors: S
authors: Novault
authors: Fabrice
authors: F
authors: André
authors: Laurence
authors: L
authors: Zitvogel
mesh_terms: D000818:Animals; D017951:Antigen Presentation; D000951:Antigens, Neoplasm / Q000008:administration & dosage / Q000627:therapeutic use; D003713:Dendritic Cells / Q000276:immunology / Q000648:ultrastructure; D011992:Endosomes / Q000276:immunology* / Q000637:transplantation; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D008545:Melanoma / Q000628:therapy; D051379:Mice; D009369:Neoplasms / Q000628:therapy*; D016896:Treatment Outcome
chemical_list: D000951:Antigens, Neoplasm